PortalPublikationenBAZ2A (TIP5) is involved in epigenetic alterations in prosta...

BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence

Standard

BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. / Gu, Lei; Frommel, Sandra C; Oakes, Christopher C; Simon, Ronald; Grupp, Katharina; Gerig, Cristina Y; Bär, Dominik; Robinson, Mark D; Baer, Constance; Weiss, Melanie; Gu, Zuguang; Schapira, Matthieu; Kuner, Ruprecht; Sültmann, Holger; Provenzano, Maurizio; Yaspo, Marie-Laure; Brors, Benedikt; Korbel, Jan; Schlomm, Thorsten; Sauter, Guido; Eils, Roland; Plass, Christoph; Santoro, Raffaella; ICGC Project on Early Onset Prostate Cancer.

in: NAT GENET, Jahrgang 47, Nr. 1, 01.01.2015, S. 22-30.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gu, L, Frommel, SC, Oakes, CC, Simon, R, Grupp, K, Gerig, CY, Bär, D, Robinson, MD, Baer, C, Weiss, M, Gu, Z, Schapira, M, Kuner, R, Sültmann, H, Provenzano, M, Yaspo, M-L, Brors, B, Korbel, J, Schlomm, T, Sauter, G, Eils, R, Plass, C, Santoro, R & ICGC Project on Early Onset Prostate Cancer 2015, 'BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence', NAT GENET, Jg. 47, Nr. 1, S. 22-30. https://doi.org/10.1038/ng.3165

APA

Gu, L., Frommel, S. C., Oakes, C. C., Simon, R., Grupp, K., Gerig, C. Y., Bär, D., Robinson, M. D., Baer, C., Weiss, M., Gu, Z., Schapira, M., Kuner, R., Sültmann, H., Provenzano, M., Yaspo, M-L., Brors, B., Korbel, J., Schlomm, T., ... ICGC Project on Early Onset Prostate Cancer (2015). BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. NAT GENET, 47(1), 22-30. https://doi.org/10.1038/ng.3165

Vancouver

Gu L, Frommel SC, Oakes CC, Simon R, Grupp K, Gerig CY et al. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. NAT GENET. 2015 Jan 1;47(1):22-30. https://doi.org/10.1038/ng.3165

Bibtex

@article{ee2d0a509e494629809fa96703406f15,
title = "BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence",
abstract = "Prostate cancer is driven by a combination of genetic and/or epigenetic alterations. Epigenetic alterations are frequently observed in all human cancers, yet how aberrant epigenetic signatures are established is poorly understood. Here we show that the gene encoding BAZ2A (TIP5), a factor previously implicated in epigenetic rRNA gene silencing, is overexpressed in prostate cancer and is paradoxically involved in maintaining prostate cancer cell growth, a feature specific to cancer cells. BAZ2A regulates numerous protein-coding genes and directly interacts with EZH2 to maintain epigenetic silencing at genes repressed in metastasis. BAZ2A overexpression is tightly associated with a molecular subtype displaying a CpG island methylator phenotype (CIMP). Finally, high BAZ2A levels serve as an independent predictor of biochemical recurrence in a cohort of 7,682 individuals with prostate cancer. This work identifies a new aberrant role for the epigenetic regulator BAZ2A, which can also serve as a useful marker for metastatic potential in prostate cancer.",
keywords = "Adenocarcinoma, Cell Division, Cell Line, Tumor, Chromosomal Proteins, Non-Histone, CpG Islands, DNA Methylation, Epigenetic Repression, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Male, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Proteins, Polycomb Repressive Complex 2, Prognosis, Prostatic Neoplasms, Protein Interaction Mapping, RNA, Neoplasm, RNA, Ribosomal, Tumor Markers, Biological, Up-Regulation",
author = "Lei Gu and Frommel, {Sandra C} and Oakes, {Christopher C} and Ronald Simon and Katharina Grupp and Gerig, {Cristina Y} and Dominik B{\"a}r and Robinson, {Mark D} and Constance Baer and Melanie Weiss and Zuguang Gu and Matthieu Schapira and Ruprecht Kuner and Holger S{\"u}ltmann and Maurizio Provenzano and Marie-Laure Yaspo and Benedikt Brors and Jan Korbel and Thorsten Schlomm and Guido Sauter and Roland Eils and Christoph Plass and Raffaella Santoro and {ICGC Project on Early Onset Prostate Cancer}",
year = "2015",
month = jan,
day = "1",
doi = "10.1038/ng.3165",
language = "English",
volume = "47",
pages = "22--30",
journal = "NAT GENET",
issn = "1061-4036",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence

AU - Gu, Lei

AU - Frommel, Sandra C

AU - Oakes, Christopher C

AU - Simon, Ronald

AU - Grupp, Katharina

AU - Gerig, Cristina Y

AU - Bär, Dominik

AU - Robinson, Mark D

AU - Baer, Constance

AU - Weiss, Melanie

AU - Gu, Zuguang

AU - Schapira, Matthieu

AU - Kuner, Ruprecht

AU - Sültmann, Holger

AU - Provenzano, Maurizio

AU - Yaspo, Marie-Laure

AU - Brors, Benedikt

AU - Korbel, Jan

AU - Schlomm, Thorsten

AU - Sauter, Guido

AU - Eils, Roland

AU - Plass, Christoph

AU - Santoro, Raffaella

AU - ICGC Project on Early Onset Prostate Cancer

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Prostate cancer is driven by a combination of genetic and/or epigenetic alterations. Epigenetic alterations are frequently observed in all human cancers, yet how aberrant epigenetic signatures are established is poorly understood. Here we show that the gene encoding BAZ2A (TIP5), a factor previously implicated in epigenetic rRNA gene silencing, is overexpressed in prostate cancer and is paradoxically involved in maintaining prostate cancer cell growth, a feature specific to cancer cells. BAZ2A regulates numerous protein-coding genes and directly interacts with EZH2 to maintain epigenetic silencing at genes repressed in metastasis. BAZ2A overexpression is tightly associated with a molecular subtype displaying a CpG island methylator phenotype (CIMP). Finally, high BAZ2A levels serve as an independent predictor of biochemical recurrence in a cohort of 7,682 individuals with prostate cancer. This work identifies a new aberrant role for the epigenetic regulator BAZ2A, which can also serve as a useful marker for metastatic potential in prostate cancer.

AB - Prostate cancer is driven by a combination of genetic and/or epigenetic alterations. Epigenetic alterations are frequently observed in all human cancers, yet how aberrant epigenetic signatures are established is poorly understood. Here we show that the gene encoding BAZ2A (TIP5), a factor previously implicated in epigenetic rRNA gene silencing, is overexpressed in prostate cancer and is paradoxically involved in maintaining prostate cancer cell growth, a feature specific to cancer cells. BAZ2A regulates numerous protein-coding genes and directly interacts with EZH2 to maintain epigenetic silencing at genes repressed in metastasis. BAZ2A overexpression is tightly associated with a molecular subtype displaying a CpG island methylator phenotype (CIMP). Finally, high BAZ2A levels serve as an independent predictor of biochemical recurrence in a cohort of 7,682 individuals with prostate cancer. This work identifies a new aberrant role for the epigenetic regulator BAZ2A, which can also serve as a useful marker for metastatic potential in prostate cancer.

KW - Adenocarcinoma

KW - Cell Division

KW - Cell Line, Tumor

KW - Chromosomal Proteins, Non-Histone

KW - CpG Islands

KW - DNA Methylation

KW - Epigenetic Repression

KW - Follow-Up Studies

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Male

KW - Neoplasm Invasiveness

KW - Neoplasm Metastasis

KW - Neoplasm Proteins

KW - Polycomb Repressive Complex 2

KW - Prognosis

KW - Prostatic Neoplasms

KW - Protein Interaction Mapping

KW - RNA, Neoplasm

KW - RNA, Ribosomal

KW - Tumor Markers, Biological

KW - Up-Regulation

U2 - 10.1038/ng.3165

DO - 10.1038/ng.3165

M3 - SCORING: Journal article

C2 - 25485837

VL - 47

SP - 22

EP - 30

JO - NAT GENET

JF - NAT GENET

SN - 1061-4036

IS - 1

ER -